Microsatellite Instability clinical trials at UCSD

2 in progress, 1 open to eligible people

STK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors
open to eligible people ages 18 years and up
This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors.
La Jolla, California and other locations
RP1 Monotherapy and RP1 in Combination With Nivolumab
Sorry, not currently recruiting here
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
La Jolla, California and other locations

Last updated: March 20, 2025

STK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors